Zoledronic Acid Improves Muscle Function in Healthy Mice Treated with Chemotherapy.
BISPHOSPHONATE
BONE LOSS
CACHEXIA
CHEMOTHERAPY
MUSCLE WEAKNESS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
09
07
2019
revised:
18
09
2019
accepted:
05
10
2019
pubmed:
16
10
2019
medline:
3
7
2021
entrez:
16
10
2019
Statut:
ppublish
Résumé
Carboplatin is a chemotherapy drug used to treat solid tumors but also causes bone loss and muscle atrophy and weakness. Bone loss contributes to muscle weakness through bone-muscle crosstalk, which is prevented with the bisphosphonate zoledronic acid (ZA). We treated mice with carboplatin in the presence or absence of ZA to assess the impact of bone resorption on muscle. Carboplatin caused loss of body weight, muscle mass, and bone mass, and also led to muscle weakness as early as 7 days after treatment. Mice treated with carboplatin and ZA lost body weight and muscle mass but did not lose bone mass. In addition, muscle function in mice treated with ZA was similar to control animals. We also used the anti-TGFβ antibody (1D11) to prevent carboplatin-induced bone loss and showed similar results to ZA-treated mice. We found that atrogin-1 mRNA expression was increased in muscle from mice treated with carboplatin, which explained muscle atrophy. In mice treated with carboplatin for 1 or 3 days, we did not observe any bone or muscle loss, or muscle weakness. In addition, reduced caloric intake in the carboplatin treated mice did not cause loss of bone or muscle mass, or muscle weakness. Our results show that blocking carboplatin-induced bone resorption is sufficient to prevent skeletal muscle weakness and suggests another benefit to bone therapy beyond bone in patients receiving chemotherapy. © 2019 American Society for Bone and Mineral Research.
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Imidazoles
0
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
368-381Informations de copyright
© 2019 American Society for Bone and Mineral Research.
Références
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-95.
Remels AH, Gosker HR, Langen RC, Schols AM. The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol. 2013;114(9):1253-62.
Von Roenn JH, Roth EL, Craig R. HIV-related cachexia: potential mechanisms and treatment. Oncology. 1992;49(Suppl 2):50-4.
von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2016;7(5):507-9.
von Haehling S, Ebner N, Dos Santos MR, Springer J, Anker SD. Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol. 2017;14(6):323-41.
Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19(1):3.
Vagnildhaug OM, Balstad TR, Almberg SS, et al. A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 2018;26(6):1871-80.
Li R, Dalton, Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 2018;47:6645-53.
Rapoport BL, Demetriou GS, Moodley SD, Benn CA. When and how do I use Neoadjuvant chemotherapy for breast cancer? Curr Treat Options Oncol. 2014;15:86-98.
Brabec V, Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat. 2005;8:131-46.
Hain BA, Xu H, Wilcox JR, Mutua D, Waning DL. Chemotherapy-induced loss of bone and muscle mass in a mouse model of breast cancer bone metastases and cachexia. JCSM Rapid Commun. 2019;2(1):1-18.
Waning DL, Mohammad KS, Reiken S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21:1262-71.
Willemse PM, Hamdy NA, Kam ML de, Burggraaf J, Osanto S. Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment. J Clin Endocrinol Metab. 2014;99(11):4101-8.
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570-93.
Bischoff-Ferrari HA. The role of falls in fracture prediction. Curr Osteoporos Rep. 2011;9(3):116-21.
Fan C, Georgiou KR, McKinnon RA, Keefe DMK, Howe PRC, Xian CJ. Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab. 2016;34:277-90.
Barreto R, Kitase Y, Matsumoto T, et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep. 2017;7(1):14470.
Rana T, Chakrabarti A, Freeman M, Biswas S. Doxorubicin-mediated bone loss in breast cancer bone metastases is driven by an interplay between oxidative stress and induction of TGFbeta. PLoS One. 2013;8(10):e78043.
Rakel A, Boucher A, Ste-Marie LG. Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging. 2011;6:89-99.
Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10(1):52-62.
Wright JD, Tergas AI, Ananth CV, et al. Quality and outcomes of treatment of hypercalcemia of malignancy. Cancer Invest. 2015;33(8):331-9.
Alonso N, Calero-Paniagua I, Del Pino-Montes J. Clinical and genetic advances in Paget's disease of bone: a review. Clin Rev Bone Miner Metab. 2017;15(1):37-48.
Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38(5):617-27.
Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1970;1(1):12-8.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45.
Clezardin P. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep. 2013;2:267.
Sun QA, Hess DT, Nogueira L, et al. Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4. Proc Natl Acad Sci U S A. 2011;108(38):16098-103.
Scicchitano BM, Faraldi M, Musaro A. The proteolytic systems of muscle wasting. Recent Adv DNA Gene Seq. 2015;9(1):26-35.
Stacchiotti A, Rovetta F, Ferroni M, et al. Taurine rescues cisplatin-induced muscle atrophy in vitro: a morphological study. Oxid Med Cell Longev. 2014;2014:1-11.
Sakai H, Kimura M, Isa Y, et al. Effect of acute treadmill exercise on cisplatin-induced muscle atrophy in the mouse. Pflugers Archiv. 2017;469(11):1495-505.
Yoon MS. mTOR as a key regulator in maintaining skeletal muscle mass. Front Physiol. 2017;8:788.
White JP, Baynes JW, Welle SL, et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. PLoS One. 2011;6(9):e24650.
Bentzinger CF, Lin S, Romanino K, et al. Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet Muscle. 2013;3(1):6.
Gordon BS, Kelleher AR, Kimball SR. Regulation of muscle protein synthesis and the effects of catabolic states. Int J Biochem Cell Biol. 2013;45(10):2147-57.
Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399-412.
Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015;54(3):340-8.
van Hennik MB, van der Vijgh WJ, Klein I, et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res. 1987;47(23):6297-301.
Bonetto A, Andersson DC, Waning DL. Assessment of muscle mass and strength in mice. Bonekey Rep. 2015;4:732.
Yamada T, Place N, Kosterina N, et al. Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum. 2009;60(11):3280-9.
Wen Y, Murach KA, Vechetti IJ Jr, et al. MyoVision: software for automated high-content analysis of skeletal muscle immunohistochemistry. J Appl Physiol. 2018;124(1):40-51.
Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGF-beta signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010;25(11):2419-26.
Sandri M, El Meslemani AH, Sandri C, et al. Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol. 2001;60(3):302-12.
Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer. 2001;84(8):1135-40.
Rha SY, Lee J. Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. Support Care Cancer. 2017;25(5):1519-27.
Axelsen CT, Jensen AB, Jakobsen EH, Bechmann T. Bone loss during neoadjuvant/adjuvant chemotherapy for early stage breast cancer: a retrospective cohort study. Mol Clin Oncol. 2018;8(6):767-72.
Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11(10):1121-31.
Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-405.
Yee AJ, Raje NS. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Future Oncol. 2018;14(3):195-203.
Zheng GZ, Chang B, Lin FX, et al. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours. Eur J Cancer Care (Engl). 2017;26(6):1-7.
Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, et al. Efficacy of Neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res. 2017;23(3):649-57.
Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497-508.
Shandala T, Shen Ng Y, Hopwood B, Yip YC, Foster BK, Xian CJ. The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227(7):2889-97.
Stine KC, Wahl EC, Liu L, et al. Cisplatin inhibits bone healing during distraction osteogenesis. J Orthop Res. 2014;32(3):464-70.
Matheus HR, Ervolino E, Faleiros PL, et al. Cisplatin chemotherapy impairs the peri-implant bone repair around titanium implants: an in vivo study in rats. J Clin Periodontol. 2018;45(2):241-52.
Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332(5):305-11.
Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 2012;31(3-4):569-78.
Waning DL, Guise TA. Cancer-associated muscle weakness: what's bone got to do with it? Bonekey Rep. 2015;4:691.
Sakai R, Eto Y. Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol. 2001;180(1-2):183-8.
Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9(4):443-7.
Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother. 2005;39(1):128-35.
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9-17.
Molina P, Carrero JJ, Bover J, et al. Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2017;8(5):686-701.
Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis. 1998;32(5):1-8.
Dawson-Hughes B. Vitamin D and muscle function. J Steroid Biochem Mol Biol. 2017;173:313-6.
Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. 2011;25(4):585-91.
Girgis CM, Cha KM, So B, et al. Mice with myocyte deletion of vitamin D receptor have sarcopenia and impaired muscle function. J Cachexia Sarcopenia Muscle. 2019:1-13. DOI:10.1002/jcsm.12460.
Conte E, Camerino GM, Mele A, et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle. 2017;8:386-404.
Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153-65.
Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients 2017;9(4):1-15.
Aono Y, Hasegawa H, Yamazaki Y, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011;26(4):803-10.
Albadawi H, Haurani MJ, Oklu R, et al. Differential effect of zoledronic acid on human vascular smooth muscle cells. J Surg Res. 2013;182(2):339-46.
Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig. 2013;33(2):117-22.
Damrauer JS, Stadler ME, Acharyya S, Baldwin AS, Couch ME, Guttridge DC. Chemotherapy-induced muscle wasting: association with NF-κB and cancer cachexia. Eur J Transl Myol. 2018;28:7590.
Fanzani A, Zanola A, Rovetta F, Rossi S, Aleo MF. Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol Appl Pharmacol. 2011;250(3):312-21.
Gangadharan A, Choi SE, Hassan A, et al. Protein calorie malnutrition, nutritional intervention and personalized cancer care. Oncotarget. 2017;8(14):24009-30.
Kotler DP. Cachexia. Ann Intern Med. 2000;133(8):622-34.
Sakai H, Sagara A, Arakawa K, et al. Mechanisms of cisplatin-induced muscle atrophy. Toxicol Appl Pharmacol. 2014;278:190-9.